A Phased Desensitization Protocol With Rituximab and Bortezomib for Highly HLA-sensitized Transplant Patients.
- Conditions
- DSA-positive Transplant Patients
- Registration Number
- JPRN-UMIN000011914
- Lead Sponsor
- Transplantation Surgery, Hiroshima University Hospital
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 30
Not provided
Patients with current or recent severe systemic infections requiring treatment (systemic antibiotics, antivirals, or antifungals). Serious diarrhea, active ulcer or uncontrolled diabetes likely to interfere with participation in this clinical study. Serious medical or psychiatric illness likely to interfere with participation in this clinical study. Myocardial infarction, uncontrolled angina, severe uncontrolled ventricular arrhythmias, or electrocardiographic evidence of acute ischemia or active conduction system abnormalities. Known history of allergy to rituximab or bortezomib. History of severe allergic or anaphylactic reactions to humanized or murine monoclonal antibodies. Female subject is pregnant or breast-feeding. Any other clinically significant medical disease or condition that, in the Investigator's opinion, may interfere with protocol adherence or a subject's ability to give informed consent.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method